Ankang Li, Ph.D., J.D., CFA
Chief Strategy and Financial Officer
Chief Executive Officer of TSB Therapeutics
Dr. Li is accountable for Brii’s corporate finance & accounting, reporting & control, legal, investor relations, corporate communications, operation excellence and strategy development.
Dr. Li has more than 10 years of experience in investment banking, business development, legal transaction and biomedical research. Before joining Brii Bio, he was the CFO of Terns Biopharmaceuticals to develop and deploy financial and corporate strategies and budget. Prior to Terns, Dr. Li was the Executive Director of Healthcare Investment Banking at Goldman Sachs responsible for Asia ex-Japan investment banking and led many high-profile IPOs for biotechnology and other healthcare clients. Dr. Li also worked in Merck (known as MSD outside of the U.S. and Canada) Asia Pacific Innovation Hub, overseeing business development and licensing transactions in the region. Before that Dr. Li worked at both Davis Polk and Ropes & Gray, advising clients on capital markets and M&A transactions. His working career started in the Salk Institute as a postdoctoral biomedical researcher.
Ankang Li received a Juris Doctor degree from the University of Chicago Law School, a Ph.D. degree in Biomedical Sciences from Baylor College of Medicine, a Master of Science degree in Biological Sciences from the National University of Singapore, and a Bachelor of Science degree in Biochemistry from Fudan University. He is also a chartered Financial Analyst (CFA).